Cover Image
市場調查報告書

Rigel Pharmaceuticals, Inc.的產品平台分析

Rigel Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226229
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
Rigel Pharmaceuticals, Inc.的產品平台分析 Rigel Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月29日 內容資訊: 英文 38 Pages
簡介

Rigel Pharmaceuticals, Inc.ha是研究、發明治療發炎疾病及自體免疫疾病用的小分子醫藥品的臨床階段的醫藥品開發企業。

本報告提供Rigel Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Rigel Pharmaceuticals, Inc.的基本資料

Rigel Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Rigel Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Rigel Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Rigel Pharmaceuticals, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Rigel Pharmaceuticals, Inc.:藥物簡介

  • fostamatinib disodium
  • R-348
  • R-118
  • Atropy抑制劑
  • PKCsorter抑制劑計劃

Rigel Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Rigel Pharmaceuticals, Inc.:最近的開發平台趨勢

Rigel Pharmaceuticals, Inc.:暫停中的計劃

Rigel Pharmaceuticals, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
  • fostamatinib disodium
  • R-333
  • R-343
  • R-548

Rigel Pharmaceuticals, Inc.:企業發表

Rigel Pharmaceuticals, Inc.:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07131CDB

Summary

Global Markets Direct's, 'Rigel Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Rigel Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Rigel Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Rigel Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Rigel Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Rigel Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Rigel Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Rigel Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Rigel Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Rigel Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Rigel Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Rigel Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Rigel Pharmaceuticals, Inc. Snapshot
    • Rigel Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Rigel Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Rigel Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Rigel Pharmaceuticals, Inc. - Pipeline Products Glance
    • Rigel Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Rigel Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Rigel Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Rigel Pharmaceuticals, Inc. - Drug Profiles
    • fostamatinib disodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • R-348
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Growth and Differentiation Factor 8 for Ventilator Atrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize TGF Beta Receptor for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Rigel Pharmaceuticals, Inc. - Pipeline Analysis
    • Rigel Pharmaceuticals, Inc. - Pipeline Products by Target
    • Rigel Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Rigel Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Rigel Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Rigel Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Rigel Pharmaceuticals, Inc. - Dormant Projects
  • Rigel Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • fostamatinib disodium
      • R-333
      • R-548
  • Rigel Pharmaceuticals, Inc. - Company Statement
  • Rigel Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Rigel Pharmaceuticals, Inc., Key Information
  • Rigel Pharmaceuticals, Inc., Key Facts
  • Rigel Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Rigel Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Rigel Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Rigel Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Rigel Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Rigel Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Rigel Pharmaceuticals, Inc. - Phase III, 2015
  • Rigel Pharmaceuticals, Inc. - Phase II, 2015
  • Rigel Pharmaceuticals, Inc. - Preclinical, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Rigel Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Rigel Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Rigel Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Rigel Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Rigel Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Rigel Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Rigel Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top